Tazeen Ahmad
Stock Analyst at B of A Securities
(2.49)
# 2,308
Out of 4,863 analysts
206
Total ratings
46.45%
Success rate
-0.4%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $174.98 | +23.44% | 10 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $18 → $23 | $22.10 | +4.07% | 14 | Jun 5, 2025 | |
| PRTA Prothena Corporation | Downgrades: Underperform | $22 → $4 | $5.62 | -28.76% | 6 | May 28, 2025 | |
| STRO Sutro Biopharma | Maintains: Underperform | $1 → $0.8 | $0.91 | -12.31% | 3 | May 19, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $28 → $27 | $14.35 | +88.15% | 3 | May 19, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $41 → $23 | $18.29 | +25.75% | 7 | May 9, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $55 → $68 | $51.07 | +33.15% | 17 | May 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $61.52 | +10.53% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $308.64 | +5.30% | 3 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $7.25 | +286.21% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $53.67 | +30.43% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $4.37 | +815.33% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $125.31 | +42.85% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $12.55 | +75.30% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.44 | +108.33% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $71.00 | +26.76% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.94 | +152.74% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $9.09 | -33.96% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $106.87 | +40.36% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.64 | -69.88% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $556.80 | +9.02% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $20.54 | +937.00% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $37.11 | +104.80% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $3.99 | +251.32% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.42 | +313.22% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.26 | +378.09% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.77 | +71.04% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $16.31 | -32.56% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $10.30 | -2.91% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.29 | -39.21% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.01 | +497.01% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $10.00 | +50.00% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $43.51 | +37.90% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.22 | +1,216.87% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.91 | +333.91% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $172.90 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.50 | +3,057.89% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.87 | +214.14% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $24.33 | +97.29% | 6 | Oct 10, 2018 |
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $174.98
Upside: +23.44%
ACADIA Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $22.10
Upside: +4.07%
Prothena Corporation
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $5.62
Upside: -28.76%
Sutro Biopharma
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.91
Upside: -12.31%
Denali Therapeutics
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $14.35
Upside: +88.15%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Neutral
Price Target: $41 → $23
Current: $18.29
Upside: +25.75%
PTC Therapeutics
May 9, 2025
Upgrades: Buy
Price Target: $55 → $68
Current: $51.07
Upside: +33.15%
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $61.52
Upside: +10.53%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $308.64
Upside: +5.30%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.25
Upside: +286.21%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $53.67
Upside: +30.43%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $4.37
Upside: +815.33%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $125.31
Upside: +42.85%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.55
Upside: +75.30%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.44
Upside: +108.33%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $71.00
Upside: +26.76%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.94
Upside: +152.74%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $9.09
Upside: -33.96%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $106.87
Upside: +40.36%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.64
Upside: -69.88%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $556.80
Upside: +9.02%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $20.54
Upside: +937.00%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $37.11
Upside: +104.80%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $3.99
Upside: +251.32%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.42
Upside: +313.22%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.26
Upside: +378.09%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.77
Upside: +71.04%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $16.31
Upside: -32.56%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $10.30
Upside: -2.91%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.29
Upside: -39.21%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.01
Upside: +497.01%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $10.00
Upside: +50.00%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $43.51
Upside: +37.90%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.22
Upside: +1,216.87%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.91
Upside: +333.91%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $172.90
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.50
Upside: +3,057.89%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.87
Upside: +214.14%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $24.33
Upside: +97.29%